Homburger advises CDR‑Life on global licensing agreement with Boehringer Ingelheim for antibody‑based autoimmune therapy

"Homburger advised CDR‑Life on a global licensing agreement with Boehringer Ingelheim to develop an antibody‑based molecule for autoimmune diseases. Under the deal CDR‑Life may receive up to CHF 456 million, including CHF 38 million in upfront and near‑term payments, plus tiered royalties on future sales."

Homburger advised CDR‑Life in its global licensing agreement with Boehringer Ingelheim. The agreement concerns the joint development of an antibody‑based molecule aimed at treating autoimmune diseases. It follows the parties' prior collaboration on an investigational antibody fragment and establishes a framework under which Boehringer Ingelheim will take forward development of the candidate. Under the terms of the licence, CDR‑Life is eligible to receive up to a total of CHF 456 million in payments. That figure includes CHF 38 million in upfront and near‑term payments and is accompanied by tiered royalties on any future sales. Homburger represented CDR‑Life with a team composed by: Luca Dal Molin (IP/IT, team lead), Richard Stäuber (regulatory) and Joel Fink (IP/IT).

Homburger advises CDR‑Life on global licensing agreement with Boehringer Ingelheim for antibody‑based autoimmune therapy

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads